Sunovion Pharmaceuticals Inc. Release: Once-Daily Aptiom® (Eslicarbazepine Acetate) For The Adjunctive Treatment Of Partial-Onset Seizures Now Available In U.S. Pharmacies
4/7/2014 10:15:05 AM
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) announced that Aptiom® (eslicarbazepine acetate), a once-daily antiepileptic drug (AED) indicated for use as adjunctive treatment of partial-onset seizures, is now available by prescription in pharmacies across the United States. APTIOM, a voltage-gated sodium channel blocker, is a new chemical entity approved by the U.S. Food and Drug Administration (FDA) on November 8, 2013, and is available in four tablet strengths (200 mg, 400 mg, 600 mg and 800 mg), which can be taken whole or crushed, with or without food. APTIOM is not classified as a controlled substance by the FDA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by